About Morphocell Technologies
Morphocell Technologies is a company based in Montreal (Canada) founded in 2018. Morphocell Technologies has raised $50 million across 3 funding rounds from investors including CQDM, Invest Quebec and CDP Venture Capital. Morphocell Technologies offers products and services including ReLiver. Morphocell Technologies operates in a competitive market with competitors including NGM Biopharmaceuticals, Avidity Biosciences, Nimbus Therapeutics, Univercells and Sutro Biopharma, among others.
- Headquarter Montreal, Canada
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website morphocell.com
- Social LinkedIn X
- Total Equity Funding$50M (USD)
in 3 rounds
- Latest Funding Round$10M (USD), Series A
Dec 2025
- InvestorsCQDM
& 3 more
Products & Services of Morphocell Technologies
Morphocell Technologies offers a comprehensive portfolio of products and services, including ReLiver.
Develops tissue for treating liver diseases via advanced engineering.
Funding Insights of Morphocell Technologies
Morphocell Technologies has successfully raised a total of $50M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $10 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $50M
- Total Rounds 3
- Last Round Series A — $10M
- Investors Count 4
All 3 funding rounds of Morphocell Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2025 | $10M | Series A | – | Invest Quebec, CDP Venture Capital | – |
| Feb 2024 | $40M | Series A | – | Genson Capital | – |
| Jul 2021 | – | Seed | – | CQDM | – |
4 investors in total: 4 institutional.
Investors in Morphocell Technologies
Morphocell Technologies has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include CQDM, Invest Quebec and CDP Venture Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
CQDM is focused on facilitating biopharma innovation through funding. | – | cqdm.org | Montreal, Canada | |
Venture capital and fund of funds focused on multiple sectors | – | cdpventurecapital.it | - | |
- | – | gensoncapital.tcc.mode | - | |
Business guidance for corporate companies and startups | – | investquebec.com | - |
Investor details for Morphocell Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Morphocell Technologies
5 people are tracked at Morphocell Technologies (5 in leadership).
| Name | Role | Group |
|---|---|---|
Vincent Ling | Chief Business Officer | Leadership |
Massimiliano Paganelli | Co-Founder, President and Chief Executive Officer | Leadership |
Calley Hirsch | Vice President, Preclinical Development | Leadership |
Panos C. | Chief Development Officer | Leadership |
Patrick Bedford | Vice President, Regulatory Affairs | Leadership |
Complete people profiles for Morphocell Technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Morphocell Technologies
3 dated milestones of Morphocell Technologies across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Morphocell Technologies is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $10.0M.
Competitors of Morphocell Technologies
Morphocell Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Avidity Biosciences, Nimbus Therapeutics, Univercells and Sutro Biopharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| straumann.com | 1954 | Basel, Switzerland | – | – | Dental implants and regenerative dentistry products are developed. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| judges.uk.com | 2002 | London, United Kingdom | – | 622 | Acquisition and development of scientific instrument businesses is conducted. | |
| altimmune.com | 1997 | Gaithersburg, United States | $58M | 17 | Vaccines for infectious diseases and solid tumors are developed. |
Detailed competitors of Morphocell Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Morphocell Technologies
The website of Morphocell Technologies (morphocell.com) receives about 2.5K visits a month.
- Monthly visits2.5K
▼ 37.2% vs previous month
Latest news on Morphocell Technologies
Complete news archive for Morphocell Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Morphocell Technologies
10 companies that operate in the same segment as Morphocell Technologies (Metabolic Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Developer of cortisol modulators for the treatment of various diseases | 1998 | Menlo Park, California, United States | – | USD 761.41 M | 500 | |
Developer of therapies for the treatment of endocrine-related diseases and cancers | 2008 | San Diego, California, United States | USD 103.5 M | USD 1.04 M | 437 | |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | 2009 | Cambridge, Massachusetts, United States | USD 685 M | – | 81 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Solutions for biomarker discovery and diagnostic testing are provided. | 2000 | Morrisville, United States | USD 165.87 M | – | – | |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | 2007 | Fremont, California, United States | USD 61.1 M | USD 407.32 M | 395 | |
Biologics are developed for cardio-metabolic and liver diseases. | 2007 | San Francisco, California, United States | USD 358.87 M | USD 330.53 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Morphocell Technologies
Morphocell Technologies was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Morphocell Technologies is headquartered in Montreal, Canada. It is registered at Montreal, Quebec, Canada.
Morphocell Technologies is a funded company, having raised a total of $50M across 3 funding rounds to date.
Morphocell Technologies was founded in 2018 in Montreal, Canada, within the biotechnology sector. ReLiver, an engineered liver tissue, is utilized to create an implantable device for acute-on-chronic liver failure, an extracorporeal bio-artificial liver device, and in vitro assays for drug discovery. Operations focus on advancing these medical technologies to address liver-related conditions.
Morphocell Technologies's top competitors include Sutro Biopharma, Nimbus Therapeutics and Avidity Biosciences.
Morphocell Technologies offers ReLiver.
Morphocell Technologies has 4 investors. Key investors include CQDM, Invest Quebec, CDP Venture Capital, and Genson Capital.